23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Regeneron Pharmaceuticals, Inc. › 2025-2026

Regeneron Pharmaceuticals, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Regeneron Pharmaceuticals, Inc.’s Form 8-K, filed June 17, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 7Ballot items
  • 1,055Asset managers, any item
  • 9,087Fund votes
  • June 12, 2026Meeting date

Results at a glance

Meeting of June 12, 2026: 7 items on Regeneron Pharmaceuticals, Inc.’s Form 8-K, filed June 17, 2026: 5 elected · 2 approved.

Dissent

Significant dissent: 3 directors (29.9%, 23.2%, 20.7% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Regeneron Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Regeneron Pharmaceuticals, Inc.

These tallies are Regeneron Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 17, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Regeneron Pharmaceuticals, Inc. — official shareholder meeting results, meeting held June 12, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Joseph L. Goldstein, M.D. 72,398,29730,904,254170,603 --5,543,411 70%Elected—
Elect Director: Christine A. Poon 79,409,07024,004,88059,204 --5,543,411 77%Elected—
Elect Director: David P. Schenkein, M.D. 99,241,2194,180,10751,828 --5,543,411 96%Elected—
Elect Director: Craig B. Thompson, M.D. 81,933,65121,378,567160,936 --5,543,411 79%Elected—
Elect Director: Huda Y. Zoghbi, M.D. 100,665,2342,698,397109,523 --5,543,411 97%Elected—
2. Ratification of Appointment of Independent Registered Public Accounting Firm The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 102,503,7886,443,95868,819 ---- 94%Approved—
3. Advisory Vote on Executive Compensation The resolution to approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement on Schedule 14A filed April 24, 2026 96,469,3746,898,268105,512 --5,543,411 93%Approved—

Source: Regeneron Pharmaceuticals, Inc., Form 8-K, filed with the SEC on June 17, 2026 — read the filing on EDGAR.

How asset managers voted at the Regeneron Pharmaceuticals, Inc. 2025-2026 meeting

1,055 asset managers disclosed a vote on at least one Regeneron Pharmaceuticals, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Joseph L. Goldstein, M.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 7 wordings of this item as funds reported it.

70% Majority: yes · of votes cast

FOR 70%AGAINST
FOR: 72,398,297AGAINST: 30,904,254
Details: description as filed, official tally, votes by 182 asset managers

Description as filed by funds: Election of Directors: Joseph L. Goldstein, M.D.

Regeneron Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Joseph L. Goldstein, M.D.”): 72,398,297 for, 30,904,254 against, per its Form 8-K filed June 17, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The following nominees for Class II directors were elected to serve until the 2027 Annual Meeting of Shareholders and until their successors are duly elected and qualified based upon the following votes:”
Support: 70% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 182 asset managers below reported 31,058,888 for, 8,815,478 against, 11,211 abstained, 120 not voted.

FORAGAINST
FOR: 31,058,888AGAINST: 8,815,478ABSTAIN: 11,211NOT VOTED: 120
Largest asset managers voting on “Election of Directors: Joseph L. Goldstein, M.D.” at Regeneron Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard10,063,92924,302 10For
Invesco3,728,1160 00For
Dodge & Cox3,411,6560 00For
BlackRock3,285,9293,570 00For
Fidelity1,000,1082,267,071 00Mixed
JPMorgan2,153,0870 00For
TIAA01,816,925 00Against
Putnam1,533,9880 00For
Capital Group1,278,6320 00For
State Street2,6481,273,728 00Against
T. Rowe Price871,316361 00For
Charles Schwab788,351262 00For
Loomis Sayles511,9450 00For
American Century0361,859 00Against
First Trust0361,618 00Against
Pacer Funds Trust355,7970 00For
Dimensional0268,093 00Against
Jackson National105,912147,059 00Mixed
Prudential/PGIM176,0211,777 00For
Federated Hermes177,2480 00For
WisdomTree0159,523 00Against
MASTER INVESTMENT PORTFOLIO156,0990 00For
ProShares0151,342 00Against
Equitable101,00046,894 00Mixed
Victory Capital36,660109,787 00Mixed

Showing the 25 largest of 182 asset managers. All 182 are in the interactive database (link above).

Elect Director: Christine A. Poon

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 6 wordings of this item as funds reported it.

77% Majority: yes · of votes cast

FOR 77%AGAINST
FOR: 79,409,070AGAINST: 24,004,880
Details: description as filed, official tally, votes by 182 asset managers

Description as filed by funds: Election of Directors: Christine A. Poon

Regeneron Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Christine A. Poon”): 79,409,070 for, 24,004,880 against, per its Form 8-K filed June 17, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The following nominees for Class II directors were elected to serve until the 2027 Annual Meeting of Shareholders and until their successors are duly elected and qualified based upon the following votes:”
Support: 77% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 182 asset managers below reported 34,101,720 for, 5,772,500 against, 11,210 abstained, 120 not voted.

FORAGAINST
FOR: 34,101,720AGAINST: 5,772,500ABSTAIN: 11,210NOT VOTED: 120
Largest asset managers voting on “Election of Directors: Christine A. Poon” at Regeneron Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard10,087,753331 00For
Invesco3,728,1160 00For
Dodge & Cox3,411,6560 00For
BlackRock3,287,0262,473 00For
Fidelity3,236,66530,514 00For
JPMorgan2,153,0870 00For
TIAA01,816,925 00Against
Putnam1,533,9880 00For
Capital Group1,278,6320 00For
State Street2,6481,273,728 00Against
T. Rowe Price871,316361 00For
Charles Schwab788,6130 00For
Loomis Sayles511,9450 00For
American Century0361,859 00Against
First Trust0361,618 00Against
Pacer Funds Trust355,7970 00For
Dimensional0268,093 00Against
Jackson National249,1213,850 00For
Prudential/PGIM176,0211,777 00For
Federated Hermes177,2480 00For
WisdomTree159,5230 00For
MASTER INVESTMENT PORTFOLIO156,0990 00For
ProShares0151,342 00Against
Equitable147,8940 00For
Victory Capital36,660109,787 00Mixed

Showing the 25 largest of 182 asset managers. All 182 are in the interactive database (link above).

Elect Director: David P. Schenkein, M.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 7 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 99,241,219AGAINST: 4,180,107
Details: description as filed, official tally, votes by 182 asset managers

Description as filed by funds: Election of Directors: David P. Schenkein, M.D.

Regeneron Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: David P. Schenkein, M.D.”): 99,241,219 for, 4,180,107 against, per its Form 8-K filed June 17, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The following nominees for Class II directors were elected to serve until the 2027 Annual Meeting of Shareholders and until their successors are duly elected and qualified based upon the following votes:”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 182 asset managers below reported 39,607,708 for, 265,616 against, 12,106 abstained, 120 not voted.

FOR
FOR: 39,607,708AGAINST: 265,616ABSTAIN: 12,106NOT VOTED: 120
Largest asset managers voting on “Election of Directors: David P. Schenkein, M.D.” at Regeneron Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard10,088,03450 00For
Invesco3,728,1160 00For
Dodge & Cox3,411,6560 00For
BlackRock3,289,4990 00For
Fidelity3,267,1790 00For
JPMorgan2,153,0870 00For
TIAA1,816,9250 00For
Putnam1,533,9880 00For
Capital Group1,278,6320 00For
State Street1,276,3760 00For
T. Rowe Price871,6770 00For
Charles Schwab788,6130 00For
Loomis Sayles511,9450 00For
American Century361,8590 00For
First Trust361,6180 00For
Pacer Funds Trust355,7970 00For
Dimensional268,0930 00For
Jackson National252,9710 00For
Prudential/PGIM177,7980 00For
Federated Hermes177,2480 00For
WisdomTree159,5230 00For
MASTER INVESTMENT PORTFOLIO156,0990 00For
ProShares151,3420 00For
Equitable101,00046,894 00Mixed
Victory Capital146,4470 00For

Showing the 25 largest of 182 asset managers. All 182 are in the interactive database (link above).

Elect Director: Craig B. Thompson, M.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 7 wordings of this item as funds reported it.

79% Majority: yes · of votes cast

FOR 79%AGAINST
FOR: 81,933,651AGAINST: 21,378,567
Details: description as filed, official tally, votes by 182 asset managers

Description as filed by funds: Election of Directors: Craig B. Thompson, M.D.

Regeneron Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Craig B. Thompson, M.D.”): 81,933,651 for, 21,378,567 against, per its Form 8-K filed June 17, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The following nominees for Class II directors were elected to serve until the 2027 Annual Meeting of Shareholders and until their successors are duly elected and qualified based upon the following votes:”
Support: 79% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 182 asset managers below reported 34,150,890 for, 5,723,328 against, 11,211 abstained, 120 not voted.

FORAGAINST
FOR: 34,150,890AGAINST: 5,723,328ABSTAIN: 11,211NOT VOTED: 120
Largest asset managers voting on “Election of Directors: Craig B. Thompson, M.D.” at Regeneron Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard10,087,783299 10For
Invesco3,728,1160 00For
Dodge & Cox3,411,6560 00For
BlackRock3,287,0262,473 00For
Fidelity3,236,66530,514 00For
JPMorgan2,153,0870 00For
TIAA01,816,925 00Against
Putnam1,533,9880 00For
Capital Group1,278,6320 00For
State Street2,6481,273,728 00Against
T. Rowe Price871,316361 00For
Charles Schwab788,6130 00For
Loomis Sayles511,9450 00For
American Century0361,859 00Against
First Trust0361,618 00Against
Pacer Funds Trust355,7970 00For
Dimensional0268,093 00Against
Jackson National249,1213,850 00For
Prudential/PGIM176,0211,777 00For
Federated Hermes177,2480 00For
WisdomTree159,5230 00For
MASTER INVESTMENT PORTFOLIO156,0990 00For
ProShares0151,342 00Against
Equitable101,00046,894 00Mixed
Victory Capital36,660109,787 00Mixed

Showing the 25 largest of 182 asset managers. All 182 are in the interactive database (link above).

Elect Director: Huda Y. Zoghbi, M.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 7 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 100,665,234AGAINST: 2,698,397
Details: description as filed, official tally, votes by 182 asset managers

Description as filed by funds: Election of Directors: Huda Y. Zoghbi, M.D.

Regeneron Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Huda Y. Zoghbi, M.D.”): 100,665,234 for, 2,698,397 against, per its Form 8-K filed June 17, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The following nominees for Class II directors were elected to serve until the 2027 Annual Meeting of Shareholders and until their successors are duly elected and qualified based upon the following votes:”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 182 asset managers below reported 39,584,487 for, 289,732 against, 11,211 abstained, 120 not voted.

FOR
FOR: 39,584,487AGAINST: 289,732ABSTAIN: 11,211NOT VOTED: 120
Largest asset managers voting on “Election of Directors: Huda Y. Zoghbi, M.D.” at Regeneron Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard10,088,04637 10For
Invesco3,728,1160 00For
Dodge & Cox3,411,6560 00For
BlackRock3,289,4990 00For
Fidelity3,267,1790 00For
JPMorgan2,153,0870 00For
TIAA1,816,9250 00For
Putnam1,533,9880 00For
Capital Group1,278,6320 00For
State Street1,276,3760 00For
T. Rowe Price871,6770 00For
Charles Schwab788,6130 00For
Loomis Sayles511,9450 00For
American Century361,8590 00For
First Trust361,6180 00For
Pacer Funds Trust355,7970 00For
Dimensional268,0930 00For
Jackson National252,9710 00For
Prudential/PGIM177,7980 00For
Federated Hermes177,2480 00For
WisdomTree159,5230 00For
MASTER INVESTMENT PORTFOLIO156,0990 00For
ProShares151,3420 00For
Equitable101,00046,894 00Mixed
Victory Capital146,4470 00For

Showing the 25 largest of 182 asset managers. All 182 are in the interactive database (link above).

Advisory Vote on Executive Compensation The resolution to approve, on an advisory basis, the compensation of the…

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 26 wordings of this item as funds reported it.

93% Approved · of votes cast

FOR 93%
FOR: 96,469,374AGAINST: 6,898,268

Prior year: 93.3% for (June 13, 2025 meeting) unchanged

Details: description as filed, official tally, votes by 1,055 asset managers

Description as filed by funds: Proposal to approve, on an advisory basis, compensation of the Named Executive Officers.

Regeneron Pharmaceuticals, Inc.’s own tally for this item (“3. Advisory Vote on Executive Compensation The resolution to approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement on Schedule ”): 96,469,374 for, 6,898,268 against — passed, per its Form 8-K filed June 17, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3 – Advisory Vote on Executive Compensation The resolution to approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's definitive proxy statement on Schedule 14A filed April 24, 2026 was approved based upon the following votes:”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 178 asset managers voting on “Proposal to approve, on an advisory basis, compensation of the Named Executive Officers.” at Regeneron Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard10,087,99587 10For
Invesco3,728,1160 00For
Dodge & Cox3,411,6560 00For
BlackRock3,289,4990 00For
Fidelity3,267,1790 00For
JPMorgan2,153,0870 00For
TIAA1,816,9250 00For
Putnam1,533,9880 00For
Capital Group01,278,632 00Against
State Street1,276,35818 00For
T. Rowe Price871,6770 00For
Charles Schwab788,6130 00For
Loomis Sayles511,9450 00For
American Century333,08128,778 00Mixed
First Trust361,6180 00For
Pacer Funds Trust355,7970 00For
Dimensional268,0930 00For
Jackson National252,9710 00For
Prudential/PGIM177,7980 00For
Federated Hermes177,2480 00For
WisdomTree159,5230 00For
MASTER INVESTMENT PORTFOLIO156,0990 00For
ProShares151,3420 00For
Equitable147,8940 00For
Victory Capital146,4470 00For

Fund voting reports, all 178 managers: 38,405,161 for, 1,468,309 against, 11,211 abstained, 120 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 917 asset managers voting on “Proposal to approve, on an advisory basis, compensation of the Named Executive Officers.” at Regeneron Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock4,441,0746 00For
Dodge & Cox4,216,2250 00For
Invesco4,214,3120 00For
State Street3,020,75333,716 00For
GEODE CAPITAL MANAGEMENT, LLC2,612,9410 00For
Putnam2,368,5340 00For
T. Rowe Price2,221,6130 00For
Wellington2,008,0830 00For
Nuveen2,000,851706 00For
Loomis Sayles1,603,66862,432 00For
Capital Group4,0451,445,673 00Against
Fidelity1,405,1330 00For
Vanguard1,036,4590 00For
Amundi0985,490 00Against
Charles Schwab839,2400 00For
Northern Trust792,0447,810 00For
AQR726,9160 00For
MELLON INVESTMENTS Corp538,9150 00For
Neuberger Berman510,9930 00For
Goldman Sachs483,1150 00For
Legal & General Investment Management Ltd458,0932,374 00For
American Century428,47729,447 00Mixed
Two Sigma445,5650 00For
PARAMETRIC PORTFOLIO ASSOCIATES LLC406,7940 00For
UBS0370,679 00Against

Institutional-manager reports, all 917 managers: 50,322,623 for, 5,453,229 against, 7,337 abstained, 21,654 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of Appointment of Independent Registered Public Accounting Firm The proposal to ratify the appointment of…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 7 wordings of this item as funds reported it.

94% Approved · of votes cast

FOR 94%
FOR: 102,503,788AGAINST: 6,443,958

Prior year: 94.5% for (June 13, 2025 meeting) ▼ 0.5 pts

Details: description as filed, official tally, votes by 185 asset managers

Description as filed by funds: Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

Regeneron Pharmaceuticals, Inc.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Public Accounting Firm The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the ”): 102,503,788 for, 6,443,958 against — passed, per its Form 8-K filed June 17, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Ratification of Appointment of Independent Registered Public Accounting Firm The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was approved based upon the foll…”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 185 asset managers below reported 39,819,363 for, 100,585 against, 11,210 abstained, 120 not voted.

FOR
FOR: 39,819,363AGAINST: 100,585ABSTAIN: 11,210NOT VOTED: 120
Largest asset managers voting on “Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public a” at Regeneron Pharmaceuticals, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard10,078,6919,540 00For
Invesco3,728,1160 00For
Dodge & Cox3,411,6560 00For
BlackRock3,288,926573 00For
Fidelity3,267,1790 00For
JPMorgan2,153,0870 00For
TIAA1,816,9250 00For
Putnam1,533,9880 00For
Capital Group1,278,6320 00For
State Street1,276,35818 00For
T. Rowe Price871,6770 00For
Charles Schwab788,6130 00For
Loomis Sayles511,9450 00For
American Century361,8590 00For
First Trust361,6180 00For
Pacer Funds Trust355,7970 00For
Dimensional268,0930 00For
Jackson National252,9710 00For
Prudential/PGIM177,7980 00For
Federated Hermes177,2480 00For
WisdomTree159,5230 00For
MASTER INVESTMENT PORTFOLIO156,0990 00For
ProShares151,3420 00For
Equitable147,8940 00For
Victory Capital146,4470 00For

Showing the 25 largest of 185 asset managers. All 185 are in the interactive database (link above).

Not shown here: this season’s fund filings also report 1 item from the meeting of June 13, 2025, which belongs to the 2024-2025 season. A meeting outside this season’s July 1 to June 30 window is not counted in this page’s items or in its totals of asset managers and fund votes.

Largest Regeneron Pharmaceuticals, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 104,000,000 shares outstanding at the time of that meeting.

Fund voting reports: top Regeneron Pharmaceuticals, Inc. shareholders by shares voted on “Proposal to approve, on an advisory basis, compensation of the Named Executive Officers.”, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 9.70%
2Invesco 3.58%
3Dodge & Cox 3.28%
4BlackRock 3.16%
5Fidelity 3.14%
6JPMorgan 2.07%
7TIAA 1.75%
8Putnam 1.47%
9Capital Group 1.23%
10State Street 1.23%
Institutional-manager reports: top Regeneron Pharmaceuticals, Inc. shareholders by shares voted on “Proposal to approve, on an advisory basis, compensation of the Named Executive Officers.”, 2025-2026
#Asset manager % of shares outstanding
1BlackRock 4.27%
2Dodge & Cox 4.05%
3Invesco 4.05%
4State Street 2.94%
5GEODE CAPITAL MANAGEMENT, LLC 2.51%
6Putnam 2.28%
7T. Rowe Price 2.14%
8Wellington 1.93%
9Nuveen 1.92%
10Loomis Sayles 1.60%

Reported Regeneron Pharmaceuticals, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Regeneron Pharmaceuticals, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
BlackRock8,947,735 8.60%Form 13F, quarter ended March 31, 2026
State Street4,664,478 4.49%Form 13F, quarter ended March 31, 2026
JPMorgan Chase4,311,806 4.15%Form 13F, quarter ended March 31, 2026
Franklin Templeton2,722,071 2.62%Form 13F, quarter ended March 31, 2026
T. Rowe Price2,177,527 2.09%Form 13F, quarter ended March 31, 2026
Wellington Management1,837,459 1.77%Form 13F, quarter ended March 31, 2026
Invesco1,724,478 1.66%Form 13F, quarter ended March 31, 2026
FMR (Fidelity)1,518,192 1.46%Form 13F, quarter ended March 31, 2026

Percentages above are of 104,000,000 shares outstanding, as reported by Regeneron Pharmaceuticals, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Regeneron Pharmaceuticals, Inc.'s shareholder meeting held June 12, 2026, in the 2025-2026 proxy season, 1,055 asset managers reported votes on at least one of its 7 ballot items in their SEC Form N-PX filings, covering 9,087 separate fund positions. On the most widely held item on that ballot — Proposal to approve, on an advisory basis, compensation of the Named Executive Officers. — Regeneron Pharmaceuticals, Inc.'s filing reports the proposal as approved, with 93% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Regeneron Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 17, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Regeneron Pharmaceuticals, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Regeneron Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Regeneron Pharmaceuticals (REGN) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/regeneron-pharmaceuticals-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.